Minireviews
Copyright ©The Author(s) 2022.
World J Gastroenterol. Oct 28, 2022; 28(40): 5807-5817
Published online Oct 28, 2022. doi: 10.3748/wjg.v28.i40.5807
Table 1 Main studies investigating the deleterious role of frailty, low muscle mass, sarcopenia and myosteatosis in patients undergoing pre-transplant assessment
Ref.
Patient selection
Patients, n
Sarcopenia, myosteatosis
Frailty parameters
Outcome
Results
Lai et al[15], 2019Ambulatory cirrhotic patients awaiting LT1014Non applicableLFIWaiting list mortalityFrailty: 25%. HR = 1.82; 95%CI: 1.31-2.52; P < 0.001
Fozouni et al[48], 2020LT recipients241Non applicableLFIAcute cellular rejection within 3 mo post-LTFrailty: 19%. OR = 3.3; 95%CI: 1.2-9.3; P = 0.02
Lai et al[47], 2022LT recipients1166Non applicableLFILT LOS. ICU stay. Inpatient days within 3 mo post-LT. Overall survival (1-3 and 5-yr mortality)Frailty: 21%. Prolonged LT LOS: OR = 2.00; 95%CI: 1.47-2.73. ICU stay: OR = 1.56; 95%CI: 1.12-2.14. Inpatient days within 3 mo. post-LT: OR = 1.72; 95%CI: 1.25-2.37. Overall survival: P = 0.02
Bhanji et al[41], 2018Cirrhotic patients assessed for LT675L3-MA (HU). L3-SMINon applicableHE. MortalitySarcopenia: 36%. HE: OR = 2.42; 95%CI: 1.43-4.10; P = 0.001. Mortality: Univariate HR = 2.02; 95%CI: 1.57-2.58; P < 0.001. Multivariate: HR = 2.15; 95%CI: 1.52-3.05; P < 0.001. Myosteatosis: 52%. HE: OR = 2.25; 95%CI: 1.32-3.85; P = 0.003. Mortality: Univariate: HR = 1.45; P = 0.004; 95%CI: 1.16-2.91. Multivariate: P = 0.69
Van Vugt et al[42], 2016LT candidates/recipients3804. Meta-analysisSMI. Total psoas areaNon applicableWaiting list mortality. Post-LT mortalityWaiting list mortality: HR = 1.72; 95%CI: 0.99-3.00; P = 0.02. Post-LT mortality: HR = 1.84; 95%CI: 1.11-3.05; P = 0.05
Bot et al[40], 2021ESLD patients awaiting LT262L3-SMI (cm2/m2). L3-MA (HU)Non applicableWaiting list mortalityLow SMI: HR = 2.580; 95%CI: 1.055-6.308. MA: HR = 9.124; 95%CI: 2.871-28.970
Czigany et al[24], 2020LT recipients225L3-SMI. L3-MA (HU)Non applicableMajor morbidity. ICU stay. LT LOSSarcopenia: 37%. Myosteatosis: 44%. Major morbidity: OR = 2.772; 95%CI: 1.516-5.066; P = 0.001. ICU stay: 18 ± 25 vs 11 ± 21 d, P < 0.001. LT LOS: 56 ± 55 vs 33 ± 24 d, P < 0.001